BMO Capital maintains Outperform on Pfizer, lowers target to $30
BMO Capital analyst Evan David Seigerman maintained an Outperform rating on Pfizer while lowering the price target to $30 from $34. The revised target indicates a shift in valuation expectations despite the continued positive stance on the stock.
*this image is generated using AI for illustrative purposes only.
BMO Capital analyst Evan David Seigerman maintained an Outperform rating on Pfizer while lowering the price target to $30 from $34. The revised target indicates a shift in valuation expectations despite the continued positive stance on the stock.
Rating and Price Target
The Outperform rating suggests that Pfizer is expected to perform better than the broader market or its sector peers. The reduction in the price target to $30 signals a more conservative near-term outlook compared to the previous $34 estimate.
| Metric | Value |
|---|---|
| Rating | Outperform |
| Previous Price Target | $34 |
| New Price Target | $30 |
Analyst Perspective
Evan David Seigerman's recommendation underscores confidence in Pfizer's fundamental strength, even as the price target adjustment acknowledges potential headwinds or revised earnings projections.
Historical Stock Returns for Pfizer
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.34% | -3.02% | +2.91% | -1.42% | -13.89% | -17.38% |
What specific headwinds prompted the reduction in the price target despite the Outperform rating?
How might Pfizer's upcoming product pipeline influence the revised valuation expectations?
What are the potential market reactions if Pfizer fails to meet the conservative near-term outlook?
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
